Watch CLDX. Know when insiders buy.
One email the day a filing lands. Free.
CLDX
Celldex Therapeutics, Inc.
38.78
−0.34 −0.87%
USD · close Sep 9
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
52
WATCH · shorts 52
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $3BP/E —DIV YIELD —FCF YIELD -7.95%REV TTM $158K −97.3%NET INCOME −$300.5MNET CASH —52W 22.58 – 44.87SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $22K | −97.0% | — | −$80.6M | −$73.5M | — | -0.94 | −$57.4M | $3.2M | −$60.6M | Aug 6 |
| Q1 2026 · Mar 31 | $15K | −97.8% | — | −$84.4M | −$78.7M | — | -1.18 | −$65.6M | $1.6M | −$67.2M | Aug 6 |
| Q4 2025 · Dec 31derived | $121K | −89.7% | — | −$87.2M | −$81.3M | — | -1.23 | −$63.9M | $1.3M | −$65.2M | Feb 25 |
| Q3 2025 · Sep 30 | $0 | −100.0% | — | −$73.6M | −$67M | — | -1.01 | −$48.6M | $440K | −$49.1M | Nov 10 |
| Q2 2025 · Jun 30 | $730K | −70.8% | — | −$63.9M | −$56.6M | — | -0.85 | −$44M | $728K | −$44.7M | Aug 6 |
| Q1 2025 · Mar 31 | $695K | +345.5% | — | −$62.7M | −$53.8M | — | -0.81 | −$54.4M | $265K | −$54.6M | Aug 6 |
| Q4 2024 · Dec 31derived | $1.2M | −71.6% | — | −$56M | −$47.1M | — | -0.71 | −$32.5M | $756K | −$33.2M | Feb 25 |
| Q3 2024 · Sep 30 | $3.2M | +110.3% | — | −$52.1M | −$42.1M | — | -0.64 | −$55.3M | $545K | −$55.9M | Nov 10 |
| Q2 2024 · Jun 30 | $2.5M | — | — | −$46.3M | −$35.8M | — | -0.54 | −$29.3M | $274K | −$29.6M | Nov 10 |
| Q1 2024 · Mar 31 | $156K | — | — | −$40.6M | −$32.8M | — | -0.56 | −$40.6M | $344K | −$41M | Nov 10 |
| Q4 2023 · Dec 31derived | $4.1M | — | — | −$47.6M | −$43.3M | — | -0.84 | −$32.5M | $666K | −$33.2M | Feb 25 |
| Q3 2023 · Sep 30 | $1.5M | — | — | −$41.2M | −$38.3M | — | -0.81 | −$19M | $157K | −$19.1M | Nov 6 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $1.5M | 87.1% | −$287.4M | −$258.8M | -16748.0% | -3.90 | −$210.9M | $2.7M | −$213.7M | — | — |
| FY2024 · to Dec 31 | $7M | 97.2% | −$195.1M | −$157.9M | -2248.8% | -2.45 | −$157.8M | $1.9M | −$159.7M | — | — |
| FY2023 · to Dec 31 | $6.9M | 95.6% | −$154.5M | −$141.4M | -2054.8% | -2.92 | −$107.3M | $1.8M | −$109.1M | — | — |
| FY2022 · to Dec 31 | $2.4M | 95.8% | −$115.2M | −$112.3M | -4765.6% | -2.40 | −$103.7M | $1.8M | −$105.6M | — | — |
| FY2021 · to Dec 31 | $4.7M | 97.8% | −$71.2M | −$70.5M | -1516.0% | -1.64 | −$60.9M | $1.2M | −$62.2M | — | — |
| FY2020 · to Dec 31 | $7.4M | 97.3% | −$63.4M | −$59.8M | -805.9% | -2.02 | −$40.4M | $1.6M | −$42M | — | — |
Every number comes from Celldex Therapeutics, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.